Summary of product characteristics








European Medicines Agency - Find medicine - MabThera

7/22/2014
05:30 | Author: Jeremy Rodriguez

Summary of product characteristics
European Medicines Agency - Find medicine - MabThera

This is a summary of the European public assessment report (EPAR) for. More detail is available in the summary of product characteristics.

The Committee for Medicinal Products for Human Use (CHMP) decided that MabThera’s benefits are greater than its risks and recommended that it be given marketing authorisation.

MabThera is indicated for the treatment of previously untreated patients with stage-III-IV follicular lymphoma in combination with chemotherapy.

Roche Registration Limited 6 Falcon Way Shire Park Welwyn Garden City AL7 1TW United Kingdom.

MabThera is indicated in adults for the following indications: Non-Hodgkin's lymphoma.

The effectiveness of adding MabThera to methotrexate was compared with that of adding placebo (a dummy treatment).

Comments (1)Read more



Revlimid - Summary of Product Characteristics (SPC) - (eMC)

5/21/2014
03:20 | Author: Jeremy Rodriguez

Summary of product characteristics
Revlimid - Summary of Product Characteristics (SPC) - (eMC)

Each capsule contains 2.5 mg of lenalidomide. Excipient(s) with known effect: Each capsule contains 73.5 mg of lactose, anhydrous. Each capsule contains 5.

Sign up to bookmark this SPC (already have an account? Log in ).

Each capsule contains 144.5 mg of lactose, anhydrous. Each capsule contains 10 mg of lenalidomide. Excipient(s) with known effect:.

Dosing is continued or modified based upon clinical and laboratory findings (see section 4.4). Prescribing physicians should carefully evaluate which dose of dexamethasone to use, taking into account the condition and disease status of the patient. Recommended dose adjustments during treatment and restart of treatment.

Comments (2)Read more

Procoralan - Summary of Product Characteristics (SPC) - (eMC)

3/20/2014
01:30 | Author: Jeremy Rodriguez

Summary of product characteristics
Procoralan - Summary of Product Characteristics (SPC) - (eMC)

Procoralan - Summary of Product Characteristics (SPC) by Servier Laboratories Limited.

Visual function. The use of ivabradine is not recommended immediay after a stroke since no data is available in these situations.

No data are available. The safety and efficacy of ivabradine in children aged below 18 years have not yet been established. Method of administration.

Use in patients with a low heart rate. Ivabradine is not recommended in patients with AV-block of 2nd degree.

Therefore, ivabradine is contra-indicated during breast-feeding (see section 4.3). Fertility. Animal studies indicate that ivabradine is excreted in milk.

Comments (3)Read more

Summary of Product Characteristics - Nexavar

11/29/2014
09:40 | Author: Jeremy Rodriguez

Summary of product characteristics
Summary of Product Characteristics - Nexavar

Summary of Product Characteristics. Nexavar Summary of Product Characteristics (pdf). Bayer Global · Bayer Pharma · Bayer HealthCare · General Conditions.

A multikinase inhibitor approved for cancer treatment.

This website is intended to provide information to non-US visitors.

Nexavar Summary of Product Characteristics (pdf) G.SM.ON.09.2014.1020.

Nexavar has robust evidence representing a range of patients in clinical and community settings.

Sign in or Register for more information.

This website is intended to provide information to non-US visitors.

support the use of Nexavar in the treatment of unresectable HCC.

Stratification: Age (< 60; ≥ 60 years) and geographical regions (North America/Europe/Asia).

Comments (0)

Summary of product characteristics - Site

9/28/2014
07:10 | Author: Jeremy Rodriguez

Summary of product characteristics
Summary of product characteristics - Site

Summary of product characteristics. 1 NAME OF THE MEDICINAL PRODUCT Simdax 2.5 mg/ml concentrate for solution for infusion. 2 QUALITATIVE AND.

Post hoc analyses identified systolic blood pressure < 100 mmHg or diastolic blood pressure < 60 mmHg at baseline as factors increasing the mortality risk. SURVIVE. The Simdax group had a slightly higher, although not statistically significant, death rate compared with the control group at 90 days (15% vs. 12%).

5.1 Pharmacodynamic properties Pharmacotherapeutic group: Other cardiac stimulants (calcium sensitisers), ATC code: C01CX08.

As with other medicinal products for heart failure, infusions of Simdax may be accompanied by decreases in haemoglobin and haematocrit and caution should be exercised in patients with ischaemic cardiovascular disease and concurrent anaemia.

Comments (5)Read more